Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azoxystrobin is a broad-spectrum systemic fungicide belonging to the class of methoxyacrylates, derived from naturally-occurring strobilurins. It was first marketed in 1996 and is widely used in agriculture to protect crops from fungal diseases such as rice blast, rusts, downy mildew, powdery mildew, late blight, apple scab, and Septoria. Azoxystrobin acts by inhibiting mitochondrial respiration in fungi; specifically, it blocks electron transport at the quinol outer binding site of the cytochrome b-c1 complex (complex III), preventing ATP production—a mechanism known as "Quinone Outside Inhibitor" (QoI). The compound is xylem-mobile with translaminar activity and provides both protectant and curative properties for up to four to six weeks on cereal crops. It has low acute and chronic toxicity for humans but can be highly toxic to aquatic organisms. Azoxystrobin is formulated for use in water-based sprays and marketed under several trade names primarily by Syngenta[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azoxystrobin.